US 11,807,647 B2
Crystal form of hepatitis B surface antigen inhibitor and application thereof
Zhe Cai, Shanghai (CN); Fei Sun, Shanghai (CN); and Charles Z. Ding, Shanghai (CN)
Assigned to FUJIAN AKEYLINK BIOTECHNOLOGY CO., LTD., Fujian (CN)
Appl. No. 17/760,818
Filed by FUJIAN AKEYLINK BIOTECHNOLOGY CO., LTD., Fujian (CN)
PCT Filed Sep. 18, 2020, PCT No. PCT/CN2020/116051
§ 371(c)(1), (2) Date Mar. 16, 2022,
PCT Pub. No. WO2021/052447, PCT Pub. Date Mar. 25, 2021.
Claims priority of application No. 201910887908.1 (CN), filed on Sep. 19, 2019.
Prior Publication US 2022/0402939 A1, Dec. 22, 2022
Int. Cl. C07D 498/04 (2006.01)
CPC C07D 498/04 (2013.01) [C07B 2200/13 (2013.01)] 14 Claims
 
1. A crystal form A of a compound of formula (I), wherein the crystal form has an X-ray powder diffraction pattern comprising characteristic diffraction peaks at the following 2θ angles: 6.30±0.20°, 9.30±0.20°, 9.84±0.20°, 18.68±0.20°, 20.16±0.20°, 23.06±0.20°, 24.00±0.20°, and 25.38±0.20°;

OG Complex Work Unit Chemistry